This inventor holds 4 USPTO granted patents. Top assignees: Gipharmex S.p.a., Lehner Ag. Active years: 1985-1991.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1985-1991
Title: Virginio Castagnola: Innovator in Biliary Acid Derivatives
Introduction
Virginio Castagnola is a notable inventor based in Milan, Italy. He has made significant contributions to the field of medicinal chemistry, particularly in the development of derivatives of biliary acids. With a total of four patents to his name, Castagnola's work has implications for various therapeutic applications.
Latest Patents
Among his latest patents, Castagnola has focused on the production of new derivatives of chenodeoxycholic, ursodeoxycholic, cholic, and ursocholic acids. These compounds feature a methyl group in the side chain, positioned in an alpha position relative to the carboxylic group. The patents describe the preparation of these compounds through methylation of the esters using methyl iodide in the presence of lithium-dialkylamides. This innovative approach enhances the potential for developing new therapeutic agents.
Career Highlights
Throughout his career, Virginio Castagnola has worked with prominent companies such as Gipharmex S.p.a. and Lehner Ag. His experience in these organizations has allowed him to refine his expertise in the field of pharmaceutical chemistry and contribute to groundbreaking research.
Collaborations
Castagnola has collaborated with esteemed colleagues, including Roberto Pellicciari and E Giuliano Frigerio. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Virginio Castagnola's work in the field of biliary acid derivatives showcases his commitment to advancing medicinal chemistry. His patents reflect a deep understanding of chemical processes and their potential applications in medicine. His contributions continue to influence the development of new therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile